Fisher Asset Management LLC reduced its stake in Shire PLC (NASDAQ:SHPG) by 61.4% during the second quarter, Holdings Channel reports. The firm owned 55,800 shares of the biopharmaceutical company’s stock after selling 88,675 shares during the period. Fisher Asset Management LLC’s holdings in Shire PLC were worth $9,222,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of SHPG. Whittier Trust Co. raised its position in Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 92 shares during the period. Pinnacle Bank purchased a new stake in Shire PLC during the first quarter valued at $101,000. Thompson Davis & CO. Inc. raised its stake in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 19 shares during the last quarter. FTB Advisors Inc. raised its stake in Shire PLC by 11.1% in the first quarter. FTB Advisors Inc. now owns 749 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 75 shares during the last quarter. Finally, North Star Investment Management Corp. raised its stake in Shire PLC by 8.5% in the first quarter. North Star Investment Management Corp. now owns 756 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 59 shares during the last quarter. 21.06% of the stock is owned by hedge funds and other institutional investors.
Shares of Shire PLC (SHPG) opened at 164.37 on Wednesday. Shire PLC has a one year low of $158.88 and a one year high of $209.22.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.22 by $0.41. The company had revenue of $3.57 billion during the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business’s revenue for the quarter was up 109.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.12 EPS. Analysts anticipate that Shire PLC will post $14.85 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Fisher Asset Management LLC Has $9.22 Million Stake in Shire PLC (SHPG)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/07/19/fisher-asset-management-llc-has-9-22-million-stake-in-shire-plc-shpg.html.
Several analysts have recently commented on SHPG shares. BidaskClub cut shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday. BTIG Research reissued a “buy” rating and set a $242.00 price target on shares of Shire PLC in a research note on Monday. Zacks Investment Research cut shares of Shire PLC from a “hold” rating to a “sell” rating in a research note on Monday. Sanford C. Bernstein reissued a “market perform” rating and set a $210.00 price target on shares of Shire PLC in a research note on Thursday, July 13th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $245.00 price target on shares of Shire PLC in a research note on Wednesday, July 12th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $227.45.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.
